Abstract: The risk of breast cancer is considerably increased in patients with BRCA mutation, the most common breast cancer susceptibility gene. With in-depth research of BRCA genes and the advent of PARP inhibitors, BRCA has become a new treatment target, primarily using platinum and PARP inhibitors. Platinum, the traditional chemotherapy drug, has clear efficacy in treating BRCA-mutated advanced breast cancer, while PARP inhibitors also exhibit significant efficacy as neoadjuvant or adjuvant treatment. This study reviews the progress in the treatment of BRCA-mutated breast cancer and provides guidance for the clinical diagnosis and treatment of BRCA-mutated breast cancer.